Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β

NCT01094496 is registered in ClinicalTrials.gov with Celldex Therapeutics as lead sponsor.

NCT NCT01094496
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01094496 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II, Open-Label Study of the CDX-1307 Vaccine Regimen as Neoadjuvant and Adjuvant Therapy in Patients With Newly Diagnosed Muscle-Invasive Bladder Cancer Expressing hCG-β
Lead sponsor
Celldex Therapeutics
Phase
Phase 2
Overall status
Terminated
Start date
April 30, 2010
Completion date
July 31, 2011
Enrollment
3 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

bladder cancer